In conclusion the results of this study indicated that K-ras mutation is a common event in ovarian carcinoma and more frequently present in carcinoma of mucinous histotype and lower FIGO stage. K-ras mutations could emerge as a pivotal factor for individually tailored anti-EGFR therapies. Here, KRAS is linked to carcinoma.